Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor

Antimicrob Agents Chemother. 1994 Feb;38(2):348-52. doi: 10.1128/AAC.38.2.348.

Abstract

Combinations of the human immunodeficiency virus (HIV) Tat protein antagonist Ro 24-7429 with either the HIV protease inhibitor Ro 31-8959 or the HIV reverse transcriptase inhibitors AZT (3'-azido-3'-deoxythymidine), ddC (2',3'-dideoxycytidine), ddI (2',3'-dideoxyinosine), and nevirapine were synergistic or additive in reducing HIV type 1 p24 antigen production in CEM cells or inhibiting HIV type 1-induced syncytium formation in HT4-6C cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antiviral Agents / pharmacology*
  • Benzodiazepines / pharmacology*
  • Didanosine / pharmacology
  • Drug Synergism
  • Gene Products, tat / antagonists & inhibitors*
  • HIV / drug effects
  • HIV / enzymology
  • HIV Protease Inhibitors / pharmacology*
  • HeLa Cells
  • Humans
  • Isoquinolines / pharmacology*
  • Nevirapine
  • Pyridines / pharmacology
  • Pyrroles*
  • Quinolines / pharmacology*
  • Reverse Transcriptase Inhibitors*
  • Saquinavir
  • Zalcitabine / pharmacology
  • Zidovudine / pharmacology
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • Antiviral Agents
  • Gene Products, tat
  • HIV Protease Inhibitors
  • Isoquinolines
  • Pyridines
  • Pyrroles
  • Quinolines
  • Reverse Transcriptase Inhibitors
  • tat Gene Products, Human Immunodeficiency Virus
  • Benzodiazepines
  • Ro 24-7429
  • Zidovudine
  • Zalcitabine
  • Nevirapine
  • Didanosine
  • Saquinavir